Clinical trials
Relapsed or Refractory Hematologic Malignancies clinical trials
Below are recruiting relapsed or refractory hematologic malignancies clinical trials, each written for real people, not researchers. We’re tracking 1,347 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06676059Recruiting
Substance use monitoring study with a smartphone app
This study uses a smartphone app and daily surveys to track alcohol or drug use. It aims to create a database for future research on addiction patterns and recovery.
Baltimore, MarylandAges 18–120 - NCT05444348Recruiting
Communication and care-planning support for blood cancer patients
This study tests an approach to help people with certain blood cancers and their main caregiver plan ahead and communicate more clearly about end-of-life care. It may help patients feel more supported and better prepared for difficult decisions.
AalborgAges 18 years+ - NCT04696029RecruitingPhase 2
DFMO to prevent return of high-risk or relapsed medulloblastoma
This Phase 2 study tests DFMO (a maintenance medicine) to help stop medulloblastoma from coming back or worsening after prior treatment. It focuses on children and young people with specific high-risk tumor types or tumors that have returned or not responded well to treatment.
Little Rock, ArkansasAges Up to 21 years - NCT02688894Recruiting
Molecular testing for relapsed small cell lung cancer
This study uses tumor tissue to look for molecular (biologic) changes after your small cell lung cancer comes back. It may help doctors choose the most appropriate next treatment based on what the cancer’s biology shows.
IncheonAges 20 years+ - NCT02257866Recruiting
Study of blood vessel inflammation over time
This study looks at different types of blood vessel inflammation (vasculitis) to learn more about why they happen and how they progress. By joining, you may help doctors better understand these conditions and improve future treatments.
Bethesda, MarylandAges 3 years+ - NCT07758270Recruiting
Brain scan study for multiple sclerosis treatment switch
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
St Louis, MissouriAges 40–70 - NCT04222413RecruitingPhase 1
Study of metarrestin for advanced solid tumors
This study tests an experimental drug called metarrestin for people with solid tumors that have spread or come back after standard treatment. It may help by targeting a protein involved in cancer cell growth.
Fairway, KansasAges 12–120 - NCT05391490RecruitingPhase 1
Testing donated immune cells for advanced CD19 blood cancers
This early-phase trial tests donated (allogeneic) immune cells engineered to recognize CD19, a target found on many B-cell cancers. It’s designed for people whose CD19+ cancer has come back or didn’t respond after several previous treatments, aiming to shrink tumors and control disease.
LondonAges 16–65 - NCT05285891RecruitingPhase 4
Stopping ocrelizumab in early relapsing multiple sclerosis
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
New Haven, ConnecticutAges 18–55 - NCT07753928Enrolling by invitation
MRI study of brain changes in multiple sclerosis
This study uses MRI scans to measure how the brain changes over time in people with multiple sclerosis (MS). It may help researchers understand why some people with MS experience more disability, which could lead to better treatments.
DresdenAges 18–55 - NCT05512364RecruitingPhase 3
Elacestrant for ER-positive, HER2-negative breast cancer with ctDNA relapse
This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.
AnderlechtAges 18 years+ - NCT06486051RecruitingPhase 2
CAR T-cell therapy for adults with relapsed large B-cell lymphoma
This trial tests a new treatment called atlacabtagene autoleucel, which uses your own immune cells to fight the lymphoma. It's designed for people whose lymphoma has come back or not responded to initial treatments.
Auckland, AucklandAges 18–75 - NCT05809284Recruiting
Understanding CAR T-cell therapy persistence in young patients with ALL
This study looks at why CAR T-cell therapy stops working in some children and young adults with leukemia. It aims to help doctors understand how to make this treatment last longer.
LondonAges Up to 25 years - NCT06232213Recruiting
Personalized treatment for relapsed or drug-resistant gynecological cancers
This trial tests a personalized approach to treating advanced ovarian or endometrial cancers that have come back or stopped responding to standard treatments. It uses a special model to guide which therapy might work best for you.
Beijing, Beijing MunicipalityAges 18–80 - NCT06118502Recruiting
Adaptive quit-smoking treatment for early relapse
This trial tests a flexible treatment approach for smokers who want to quit and are at risk of relapsing early. It aims to help you stay smoke-free by adjusting the support you get.
Charleston, South CarolinaAges 21 years+ - NCT05809986Recruiting
Study of ofatumumab in adults with relapsing multiple sclerosis
This is an observational study (no random treatment) that follows adults with relapsing multiple sclerosis (RMS) who are taking ofatumumab. The study aims to better understand how patients do in real-world care while completing questionnaires and other scheduled check-ins.
AmadoraAges 18–99 - NCT04373473RecruitingPhase 2
Oral stool treatment to prevent ulcerative colitis flare-ups
This study tests whether taking freeze-dried (lyophilized) donor stool material by mouth can help prevent ulcerative colitis from coming back or causing intestinal inflammation. Participants are in remission and stay on their usual treatment while receiving the study product.
Houston, TexasAges 18 years+ - NCT06069141Recruiting
Comparing syphilis treatments for people with HIV
This study compares the standard treatment for early syphilis with a combination that includes an extra antibiotic, to see which is more effective. It is for people living with HIV who have early syphilis.
Hsinchu, TaiwanAges 18 years+ - NCT07223840RecruitingPhase 2
A study of brenipatide to help former smokers stay smoke-free
This trial tests an injectable drug called brenipatide to see if it helps people who have recently quit smoking stay quit for good. The study follows participants over time and requires them to come to clinic visits.
Rogers, ArkansasAges 18–75 - NCT04715191RecruitingPhase 1
CAR T therapy for GPC3-positive pediatric solid tumors
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
Houston, TexasAges 1–21 - NCT07087314RecruitingPhase 2
Study of an injection for nephrotic syndrome in children
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
Hangzhou, ZhejiangAges 6–18 - NCT06735664RecruitingPhase 1
Zanubrutinib and odronextamab for Richter's transformation
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06654154Recruiting
Vitamin B12 as a marker for disease activity in tocilizumab patients
This study looks at whether vitamin B12 levels in the blood can help tell if your disease is active or if you have an infection while being treated with tocilizumab. The goal is to find a simple way to monitor your condition without extra invasive tests.
Clermont-FerrandAges 18 years+ - NCT06529406RecruitingPhase 4
Switching from B-cell therapy to ozanimod in MS
This study tests whether people with stable MS who have been on a B-cell depleting therapy for at least 2 years can safely switch to a daily pill called ozanimod. It aims to see if this switch keeps MS under control and may be more convenient.
Aurora, ColoradoAges 18 years+
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory hematologic malignancies?
- Yes. Clin2 currently lists 1,347 recruiting relapsed or refractory hematologic malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory hematologic malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory hematologic malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Malignancies
- Relapsed/Refractory Hematological Malignancies
- Relapsed/Refractory Multiple Myeloma
- Relapsed/Refractory Acute Myeloid Leukemia
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Relapsed/Refractory B-cell Lymphoma
- Non-Hodgkin Lymphoma Refractory/ Relapsed
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.